专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

GB180263A Improvements in wheels for tractors 未知
公开(公告)号：GB180263A
公开(公告)日：1922-05-25
申请号：GB2434221
申请日：1921-09-13
申请人： HERBERT THOMAS WICKHAM MANWARI
IPC分类号： B60B1/00
摘要： 180,263. Manwaring, H. T. W. Sept. 13,1921. Compression - spoke wheels comprise two sets of spokes, those, d, on the outer side of the wheels being arranged in a vertical plane and riveted to the flange b of the hub a and the flange e of the rim f, and those, i, on the inner side, being inclined from the hub towards the vehicle and bolted to the hub flange c and to a ring h which is bolted to the rim flange g and set at the inclination of the spokes.

2. 发明申请

US20060140909A1 Method of using adenoviral vectors with increased persistence in vivo 审中-公开
标题翻译：使用体内持续性增加的腺病毒载体的方法
公开(公告)号：US20060140909A1
公开(公告)日：2006-06-29
申请号：US11208405
申请日：2005-08-19
申请人： Thomas Wickham , Masaki Akiyama , Jason Gall
发明人： Thomas Wickham , Masaki Akiyama , Jason Gall
IPC分类号： A61K48/00 , C12N15/861
CPC分类号： C12N15/86 , A61K48/00 , C12N2710/10322 , C12N2710/10343 , C12N2710/10345 , C12N2810/405 , C12N2810/50
摘要： The invention provides a method of expressing an exogenous nucleic acid in a mammal. The method comprises slowly releasing into the bloodstream a dose of replication-deficient or conditionally-replicating adenoviral vector having reduced ability to transduce mesothelial cells and hepatocytes. The normalized average bloodstream concentration of the adenovirus over 24 hours post-administration is at least about 1%. Alternatively, the normalized average bloodstream concentration over 24 hours post-administration is at least about 5-fold greater than the normalized average bloodstream concentration for an equivalent dose of a wild-type adenoviral vector. A method of destroying tumor cells in a mammal also is provided, as is a replication-deficient adenoviral vector comprising a serotype 5 or serotype 35 adenoviral genome with a serotype 41 fiber protein, wherein the replication-deficient adenoviral vector exhibits reduced native binding to integrins.
摘要翻译：本发明提供了在哺乳动物中表达外源核酸的方法。该方法包括缓慢释放一定剂量的复制缺陷型或条件复制型腺病毒载体，其具有降低转导间皮细胞和肝细胞的能力。给药后24小时内腺病毒的归一化平均血流浓度为至少约1％。或者，给药后24小时内的标准化平均血流浓度比相当剂量的野生型腺病毒载体的归一化平均血流浓度高至少约5倍。还提供了破坏哺乳动物肿瘤细胞的方法，以及包含血清型5或具有血清型41纤维蛋白的血清型35腺病毒基因组的复制缺陷型腺病毒载体，其中复制缺陷型腺病毒载体表现出降低的天然与整联蛋白结合。

3. 发明授权

US08691771B2 Bi-specific fusion proteins for tissue repair 有权
标题翻译：用于组织修复的双特异性融合蛋白
公开(公告)号：US08691771B2
公开(公告)日：2014-04-08
申请号：US13112907
申请日：2011-05-20
申请人： Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre
发明人： Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre
IPC分类号： A61K38/16
CPC分类号： C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62
摘要： Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
摘要翻译：提供了具有治疗用途的双特异性融合蛋白，以及包含这种融合蛋白的药物组合物，以及使用这种融合蛋白修复受损组织的方法。双特异性融合蛋白通常包含：（a）与缺血相关分子结合的靶向多肽结构域; 和（b）可检测地调节细胞网络的活性的激活子结构域。

4. 发明申请

US20110293579A1 Bi-specific fusion proteins 有权
标题翻译：双特异融合蛋白
公开(公告)号：US20110293579A1
公开(公告)日：2011-12-01
申请号：US13068808
申请日：2011-05-20
申请人： Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun Lippow
发明人： Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun Lippow
IPC分类号： A61K35/12 , A61P43/00 , A61K38/02 , C07H21/00 , C07K19/00
CPC分类号： C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62
摘要： Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
摘要翻译：提供了具有治疗用途的双特异性融合蛋白，以及包含这种融合蛋白的药物组合物，以及使用这种融合蛋白修复或再生受损或患病组织的方法。双特异性融合蛋白通常包含：（a）靶向靶分子结合的靶向多肽结构域; 和（b）可检测地调节组织再生的活化剂结构域。

5. 发明申请

US20060286121A1 Adenoviral vector-based vaccines 审中-公开
标题翻译：基于腺病毒载体的疫苗
公开(公告)号：US20060286121A1
公开(公告)日：2006-12-21
申请号：US11337866
申请日：2006-01-23
申请人： Jason Gall , Thomas Wickham , William Enright , Douglas Brough , Mohammed Zuber , C. King , Gary Nabel , Cheng Cheng
发明人： Jason Gall , Thomas Wickham , William Enright , Douglas Brough , Mohammed Zuber , C. King , Gary Nabel , Cheng Cheng
IPC分类号： A61K39/12 , A61K39/395
CPC分类号： C12N15/86 , A61K48/00 , A61K2039/5256 , C07K2319/00 , C12N2710/10343 , C12N2710/10345
摘要： The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal a non-subgroup C adenoviral vector comprising an adenoviral fiber protein having an amino acid sequence comprising about 80% or more identity to an amino acid sequence encoding a subgroup C adenoviral fiber protein. The adenoviral vector further comprises a nucleic acid sequence encoding an antigen which is expressed in the mammal to induce an immune response. The invention further comprises a method of producing an adenoviral vector, and a composition comprising a serotype 41 or a serotype 35 adenoviral vector and a carrier. The invention also provides an adenoviral vector comprising a nucleic acid sequence encoding an adenoviral pIX protein operably linked to a heterologous expression control sequence, as well as a method of enhancing the stability and/or packaging capacity of an adenoviral vector.
摘要翻译：本发明提供在哺乳动物中诱导免疫应答的方法。该方法包括向哺乳动物施用非亚组C腺病毒载体，其包含具有与编码亚组C腺病毒纤维蛋白的氨基酸序列具有约80％或更高同一性的氨基酸序列的腺病毒纤维蛋白。腺病毒载体还包含编码在哺乳动物中表达以诱导免疫应答的抗原的核酸序列。本发明还包括产生腺病毒载体的方法和包含血清型41或血清型35腺病毒载体和载体的组合物。本发明还提供了一种腺病毒载体，其包含编码与异源表达控制序列可操作地连接的腺病毒pIX蛋白的核酸序列，以及增强腺病毒载体的稳定性和/或包装能力的方法。

6. 发明申请

US20050277193A1 Vectors and methods for gene transfer 审中-公开
公开(公告)号：US20050277193A1
公开(公告)日：2005-12-15
申请号：US11155845
申请日：2005-06-17
申请人： Thomas Wickham , Imre Kovesdi , Douglas Brough
发明人： Thomas Wickham , Imre Kovesdi , Douglas Brough
IPC分类号： A61K38/00 , A61K48/00 , C07K14/075 , C07K14/705 , C12N1/21 , C12N7/00 , C12N15/861 , C12N15/866 , C12N15/87
CPC分类号： C12N15/87 , A61K38/00 , A61K48/00 , C07K14/005 , C07K14/70546 , C07K2319/00 , C12N7/00 , C12N15/86 , C12N2710/10321 , C12N2710/10322 , C12N2710/10332 , C12N2710/10343 , C12N2710/10345 , C12N2710/10351 , C12N2710/14143 , C12N2810/40 , C12N2810/405 , C12N2810/60 , C12N2810/6018 , C12N2810/855 , C12N2810/856 , C12N2810/859
摘要： The present invention provides a recombinant adenovirus comprising coat proteins that lack native binding. In particular, the present invention provides a recombinant adenovirus comprising a penton base protein and a fiber protein, wherein the penton base protein and the fiber protein lack native binding. The present invention further provides a recombinant adenovirus comprising (a) a penton base protein that lacks native binding and (b) a nonnative amino acid sequence that binds a cell-surface binding site.

7. 发明授权

US09238080B2 Bi-specific fusion proteins 有权
标题翻译：双特异融合蛋白
公开(公告)号：US09238080B2
公开(公告)日：2016-01-19
申请号：US13068808
申请日：2011-05-20
申请人： Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun M. Lippow
发明人： Ulrik Nielsen , Thomas Wickham , Birgit Schoeberl , Brian Harms , Bryan Linggi , Matthew Onsum , Byron DeLaBarre , Shaun M. Lippow
IPC分类号： C07K14/475 , C12N15/62 , A61K47/48 , B82Y5/00 , A61K45/06 , C07K16/46 , A61K38/00
CPC分类号： C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62
摘要： Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair or regenerate damaged or diseased tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to a target molecule; and (b) an activator domain that detectably modulates tissue regeneration.
摘要翻译：提供了具有治疗用途的双特异性融合蛋白，以及包含这种融合蛋白的药物组合物，以及使用这种融合蛋白修复或再生受损或患病组织的方法。双特异性融合蛋白通常包含：（a）靶向靶分子结合的靶向多肽结构域; 和（b）可检测地调节组织再生的活化剂结构域。

8. 发明申请

US20080069836A1 METHOD OF USING ADENOVIRAL VECTORS WITH INCREASED IMMUNOGENICITY IN VIVO 审中-公开
标题翻译：使用腺病毒载体在体内具有增加的免疫原性的方法
公开(公告)号：US20080069836A1
公开(公告)日：2008-03-20
申请号：US11678947
申请日：2007-02-26
申请人： Gary Nabel , Cheng Cheng , Jason Gall , Thomas Wickham
发明人： Gary Nabel , Cheng Cheng , Jason Gall , Thomas Wickham
IPC分类号： A61K39/00 , A61P37/04 , C12N15/63
CPC分类号： C12N15/86 , A61K39/00 , C12N2710/10343 , Y02A50/412
摘要： The invention provides a method of inducing an immune response in a mammal. The method comprises administering to the mammal an adenoviral vector comprising (a) a subgroup C fiber protein wherein a native coxsackievirus and adenovirus receptor (CAR)-binding site is disrupted, (b) a subgroup C penton base protein wherein a native integrin-binding site is disrupted, and (c) a nucleic acid sequence encoding at least one antigen derived from an infectious agent other than an adenovirus which is expressed in the mammal to induce an immune response.
摘要翻译：本发明提供在哺乳动物中诱导免疫应答的方法。该方法包括向哺乳动物施用腺病毒载体，其包含（a）亚组C纤维蛋白，其中天然柯萨奇病毒和腺病毒受体（CAR）结合位点被破坏，（b）亚基C戊聚糖碱基蛋白，其中天然整联蛋白结合位点被破坏，和（c）编码至少一种来源于哺乳动物中表达的腺病毒以外的感染因子的抗原以诱导免疫应答的核酸序列。

9. 发明申请

US20110286976A1 BI-SPECIFIC FUSION PROTEINS 有权
标题翻译：双特异融合蛋白
公开(公告)号：US20110286976A1
公开(公告)日：2011-11-24
申请号：US13112907
申请日：2011-05-20
申请人： ULRIK NIELSEN , THOMAS WICKHAM , BIRGIT SCHOEBERL , BRIAN HARMS , BRYAN LINGGI , MATTHEW ONSUM , BYRON DELABARRE
发明人： ULRIK NIELSEN , THOMAS WICKHAM , BIRGIT SCHOEBERL , BRIAN HARMS , BRYAN LINGGI , MATTHEW ONSUM , BYRON DELABARRE
IPC分类号： A61K38/16 , C07H21/04 , A61K35/12 , C07K19/00 , A61P9/00
CPC分类号： C07K16/44 , A61K38/00 , A61K45/06 , A61K47/66 , A61K47/6811 , A61K47/6891 , B82Y5/00 , C07K14/47 , C07K14/475 , C07K14/485 , C07K14/65 , C07K16/46 , C07K2317/31 , C07K2317/76 , C07K2319/00 , C07K2319/80 , C12N15/62
摘要： Bi-specific fusion proteins with therapeutic uses are provided, as well as pharmaceutical compositions comprising such fusion proteins, and methods for using such fusion proteins to repair damaged tissue. The bi-specific fusion proteins generally comprise: (a) a targeting polypeptide domain that binds to an ischemia-associated molecule; and (b) an activator domain that that detectably modulates the activity of a cellular network.
摘要翻译：提供了具有治疗用途的双特异性融合蛋白，以及包含这种融合蛋白的药物组合物，以及使用这种融合蛋白修复受损组织的方法。双特异性融合蛋白通常包含：（a）与缺血相关分子结合的靶向多肽结构域; 和（b）可检测地调节细胞网络的活性的激活子结构域。

10. 发明申请

US20100330029A1 Cancer Treatments with Radiation and Immunocytokines 审中-公开
标题翻译：癌症治疗与放射和免疫细胞因子
公开(公告)号：US20100330029A1
公开(公告)日：2010-12-30
申请号：US12603363
申请日：2009-10-21
申请人： Thomas Wickham , Ulrike Gnad-Vogt , Sylvia Holden , Stephan G. Klinz , Karl-Josef Kallen
发明人： Thomas Wickham , Ulrike Gnad-Vogt , Sylvia Holden , Stephan G. Klinz , Karl-Josef Kallen
IPC分类号： A61K38/20 , A61P35/00 , A61P37/04
CPC分类号： A61K38/2013 , A61K38/208 , A61N5/10
摘要： The present invention is directed to a method for treating tumors and cancer cells by administering an immunocytokine following radiation treatment. This combination of treatments can stimulate an immune response at irradiated and non-irradiated sites, which is useful in eradicating cancer cells that have spread from the site of the primary tumor. In addition, immunocytokines can be administered at a dose that is less that the maximum tolerated dose, which reduces the side effects associated with immunocytokine therapy.
摘要翻译：本发明涉及通过在放射治疗后施用免疫细胞因子来治疗肿瘤和癌细胞的方法。这种治疗组合可以刺激照射和非照射部位的免疫应答，这对于根除从原发肿瘤部位扩散的癌细胞是有用的。此外，免疫细胞因子可以以小于最大耐受剂量的剂量施用，这降低了与免疫细胞因子疗法相关的副作用。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式